10% of all American adolescents and adults take an antidepressant
10% of all American adolescents and adults take an antidepressant
l
However, some of the more recently developed SSRIs were not included in those studies. In the current study, Charney and colleagues tested in a randomized controlled trial whether the relatively new SSRI, citalopram, is effective for treating depression symptoms among individuals with alcohol use disorders.
Authors compared the efficacy of citalopram (40mg per day) to placebo in 265 adult patients (n = 138 vs. 127, respectively) with alcohol use disorder who were receiving psychosocial addiction treatment (one individual and one group session weekly) across 12 weeks. Those with other substance use disorders as well as those taking a psychotropic or anti-craving medication (e.g., naltrexone) were not able to participate. The groups were similar when beginning the study, apart from greater likelihood of requiring alcohol detoxification prior to entering the study in the citalopram condition (44 vs. 26%).
Only 141 of 265 among the study sample remained in treatment across the entire 12 week study. (Though 63 of those who dropped out still provided post-treatment data).
The placebo and citalopram groups were similar on all other markers of severity, and although the citalopram group had a greater proportion of patients that needed detoxification prior to treatment, suggesting they may have been more severe to start, detoxification did not predict whether a patient had a complete vs. partial/no response to treatment (100% reduction in drinking days and drinks per drinking day).
Although SSRIs may be a commonly prescribed medication, this study adds to the body of literature suggesting:
a) they are not effective in helping reduce alcohol consumption among individuals with alcohol use disorder
b) they may not be effective in reducing depressive symptoms for this group of patients either.
It is important to determine what types of interventions, both pharmacological and psychosocial, can be most helpful.
Other antidepressants (e.g., tricyclic) appear to be more effective medications in treating depressive symptoms in those with alcohol use disorder. As the study authors suggest, however, SSRIs still could be considered once patients are abstinent for a period of time (e.g., 30 days).
Charney, D. A., Heath, L. M., Zikos, E., Palacios-Boix, J., & Gill, K. J. (2015). Poorer Drinking Outcomes with Citalopram Treatment for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial. Alcohol Clin Exp Res. doi:10.1111/acer.12802
l
However, some of the more recently developed SSRIs were not included in those studies. In the current study, Charney and colleagues tested in a randomized controlled trial whether the relatively new SSRI, citalopram, is effective for treating depression symptoms among individuals with alcohol use disorders.
Authors compared the efficacy of citalopram (40mg per day) to placebo in 265 adult patients (n = 138 vs. 127, respectively) with alcohol use disorder who were receiving psychosocial addiction treatment (one individual and one group session weekly) across 12 weeks. Those with other substance use disorders as well as those taking a psychotropic or anti-craving medication (e.g., naltrexone) were not able to participate. The groups were similar when beginning the study, apart from greater likelihood of requiring alcohol detoxification prior to entering the study in the citalopram condition (44 vs. 26%).
Only 141 of 265 among the study sample remained in treatment across the entire 12 week study. (Though 63 of those who dropped out still provided post-treatment data).
The placebo and citalopram groups were similar on all other markers of severity, and although the citalopram group had a greater proportion of patients that needed detoxification prior to treatment, suggesting they may have been more severe to start, detoxification did not predict whether a patient had a complete vs. partial/no response to treatment (100% reduction in drinking days and drinks per drinking day).
Although SSRIs may be a commonly prescribed medication, this study adds to the body of literature suggesting:
a) they are not effective in helping reduce alcohol consumption among individuals with alcohol use disorder
b) they may not be effective in reducing depressive symptoms for this group of patients either.
It is important to determine what types of interventions, both pharmacological and psychosocial, can be most helpful.
Other antidepressants (e.g., tricyclic) appear to be more effective medications in treating depressive symptoms in those with alcohol use disorder. As the study authors suggest, however, SSRIs still could be considered once patients are abstinent for a period of time (e.g., 30 days).
Charney, D. A., Heath, L. M., Zikos, E., Palacios-Boix, J., & Gill, K. J. (2015). Poorer Drinking Outcomes with Citalopram Treatment for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial. Alcohol Clin Exp Res. doi:10.1111/acer.12802
l
However, some of the more recently developed SSRIs were not included in those studies. In the current study, Charney and colleagues tested in a randomized controlled trial whether the relatively new SSRI, citalopram, is effective for treating depression symptoms among individuals with alcohol use disorders.
Authors compared the efficacy of citalopram (40mg per day) to placebo in 265 adult patients (n = 138 vs. 127, respectively) with alcohol use disorder who were receiving psychosocial addiction treatment (one individual and one group session weekly) across 12 weeks. Those with other substance use disorders as well as those taking a psychotropic or anti-craving medication (e.g., naltrexone) were not able to participate. The groups were similar when beginning the study, apart from greater likelihood of requiring alcohol detoxification prior to entering the study in the citalopram condition (44 vs. 26%).
Only 141 of 265 among the study sample remained in treatment across the entire 12 week study. (Though 63 of those who dropped out still provided post-treatment data).
The placebo and citalopram groups were similar on all other markers of severity, and although the citalopram group had a greater proportion of patients that needed detoxification prior to treatment, suggesting they may have been more severe to start, detoxification did not predict whether a patient had a complete vs. partial/no response to treatment (100% reduction in drinking days and drinks per drinking day).
Although SSRIs may be a commonly prescribed medication, this study adds to the body of literature suggesting:
a) they are not effective in helping reduce alcohol consumption among individuals with alcohol use disorder
b) they may not be effective in reducing depressive symptoms for this group of patients either.
It is important to determine what types of interventions, both pharmacological and psychosocial, can be most helpful.
Other antidepressants (e.g., tricyclic) appear to be more effective medications in treating depressive symptoms in those with alcohol use disorder. As the study authors suggest, however, SSRIs still could be considered once patients are abstinent for a period of time (e.g., 30 days).
Charney, D. A., Heath, L. M., Zikos, E., Palacios-Boix, J., & Gill, K. J. (2015). Poorer Drinking Outcomes with Citalopram Treatment for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial. Alcohol Clin Exp Res. doi:10.1111/acer.12802
151 Merrimac St., 4th Floor. Boston, MA 02114